[go: up one dir, main page]

WO2017176652A3 - Traitement de syndrome extrapyramidal à l'aide de trapidil - Google Patents

Traitement de syndrome extrapyramidal à l'aide de trapidil Download PDF

Info

Publication number
WO2017176652A3
WO2017176652A3 PCT/US2017/025788 US2017025788W WO2017176652A3 WO 2017176652 A3 WO2017176652 A3 WO 2017176652A3 US 2017025788 W US2017025788 W US 2017025788W WO 2017176652 A3 WO2017176652 A3 WO 2017176652A3
Authority
WO
WIPO (PCT)
Prior art keywords
trapidil
extrapyramidal syndrome
treating extrapyramidal
treating
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/025788
Other languages
English (en)
Other versions
WO2017176652A2 (fr
Inventor
Aarash BORDBAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinopia Biosciences Inc
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202310643240.2A priority Critical patent/CN116509869A/zh
Priority to EP17779608.3A priority patent/EP3442538B1/fr
Priority to CN201780034722.0A priority patent/CN109310700A/zh
Priority to JP2019502544A priority patent/JP7049683B2/ja
Priority to FIEP17779608.3T priority patent/FI3442538T3/fi
Priority to CA3054674A priority patent/CA3054674A1/fr
Priority to DK17779608.3T priority patent/DK3442538T3/da
Priority to AU2017246334A priority patent/AU2017246334C1/en
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Priority to ES17779608T priority patent/ES3039958T3/es
Publication of WO2017176652A2 publication Critical patent/WO2017176652A2/fr
Priority to US15/962,999 priority patent/US10350212B2/en
Publication of WO2017176652A3 publication Critical patent/WO2017176652A3/fr
Anticipated expiration legal-status Critical
Priority to US16/503,128 priority patent/US11628170B2/en
Priority to JP2022044284A priority patent/JP2022088469A/ja
Priority to US18/176,962 priority patent/US12268691B2/en
Priority to JP2024041690A priority patent/JP2024095682A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés, des combinaisons pharmaceutiques ou des kits pour la prévention ou le traitement de syndromes extrapyramidaux, par exemple la dyskinésie, la dystonie, l'acathisie ou le parkinsonisme induit par médicament, avec l'administration d'une quantité efficace thérapeutique de Trapidil, d'un dérivé, d'un métabolite, d'un promédicament, d'un analogue ou d'un sel pharmaceutiquement acceptable de ce dernier.
PCT/US2017/025788 2016-04-04 2017-04-03 Traitement de syndrome extrapyramidal à l'aide de trapidil Ceased WO2017176652A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU2017246334A AU2017246334C1 (en) 2016-04-04 2017-04-03 Treating extrapyramidal syndrome using Trapidil
EP17779608.3A EP3442538B1 (fr) 2016-04-04 2017-04-03 Traiter la dyskinésie induite par la lévodopa à l'aide du trapidil
ES17779608T ES3039958T3 (en) 2016-04-04 2017-04-03 Treating levodopa-induced dyskinesia using trapidil
JP2019502544A JP7049683B2 (ja) 2016-04-04 2017-04-03 トラピジルを使用する錐体外路症候群の処置
FIEP17779608.3T FI3442538T3 (fi) 2016-04-04 2017-04-03 Levodopan aiheuttaman dyskinesian hoito trapidiililla
CA3054674A CA3054674A1 (fr) 2016-04-04 2017-04-03 Traitement de syndrome extrapyramidal a l'aide de trapidil
DK17779608.3T DK3442538T3 (da) 2016-04-04 2017-04-03 Behandling af levodopa-induceret dyskinesi med trapidil
CN202310643240.2A CN116509869A (zh) 2016-04-04 2017-04-03 使用曲匹地尔治疗锥体外系综合征
CN201780034722.0A CN109310700A (zh) 2016-04-04 2017-04-03 使用曲匹地尔治疗锥体外系综合征
US15/962,999 US10350212B2 (en) 2016-04-04 2018-04-25 Treating extrapyramidal syndrome using trapidil
US16/503,128 US11628170B2 (en) 2016-04-04 2019-07-03 Treating extrapyramtdal syndrome using trapidil
JP2022044284A JP2022088469A (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
US18/176,962 US12268691B2 (en) 2016-04-04 2023-03-01 Treating extrapyramidal syndrome using trapidil
JP2024041690A JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317983P 2016-04-04 2016-04-04
US62/317,983 2016-04-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/962,999 Continuation US10350212B2 (en) 2016-04-04 2018-04-25 Treating extrapyramidal syndrome using trapidil

Publications (2)

Publication Number Publication Date
WO2017176652A2 WO2017176652A2 (fr) 2017-10-12
WO2017176652A3 true WO2017176652A3 (fr) 2018-05-17

Family

ID=60001402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/025788 Ceased WO2017176652A2 (fr) 2016-04-04 2017-04-03 Traitement de syndrome extrapyramidal à l'aide de trapidil

Country Status (10)

Country Link
US (3) US10350212B2 (fr)
EP (1) EP3442538B1 (fr)
JP (3) JP7049683B2 (fr)
CN (2) CN109310700A (fr)
AU (1) AU2017246334C1 (fr)
CA (1) CA3054674A1 (fr)
DK (1) DK3442538T3 (fr)
ES (1) ES3039958T3 (fr)
FI (1) FI3442538T3 (fr)
WO (1) WO2017176652A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017246334C1 (en) 2016-04-04 2022-11-17 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using Trapidil
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달
WO2021113266A1 (fr) * 2019-12-02 2021-06-10 Sinopia Biosciences, Inc. Traitement de troubles cognitifs à l'aide de trapidil
JP7730336B2 (ja) * 2020-03-26 2025-08-27 シノピア バイオサイエンシーズ，インク． 同位体標識トラピジル誘導体
WO2024053728A1 (fr) * 2022-09-09 2024-03-14 住友ファーマ株式会社 Prédiction d'état de sujet, et application de celle-ci
CN116754348B (zh) * 2023-06-06 2024-03-08 华北理工大学 基于zif-8-90材料的泡腾片、其制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117765A1 (en) * 2005-11-18 2007-05-24 Cornell Research Foundation Inc. Nicotinoyl riboside compositions and methods of use
US20090192111A1 (en) * 2007-12-01 2009-07-30 Asuragen, Inc. miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2017059113A1 (fr) * 2015-09-29 2017-04-06 Duke University Compositions et méthodes pour identifier et traiter des troubles associés à la dystonie

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
ATE159426T1 (de) 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
JPH07501073A (ja) 1991-11-22 1995-02-02 プロクター、エンド、ギャンブル、ファーマス−ティカルズ、インコーポレーテッド リゼドロネート遅延放出組成物
WO1993009668A1 (fr) 1991-11-22 1993-05-27 Affymax Technology N.V. Strategies associees pour la synthese de polymeres
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5700410A (en) 1992-10-16 1997-12-23 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) * 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (fr) 1996-01-23 2005-02-23 Affymetrix Inc Evaluation rapide de difference d'abondance d'acides nucleiques, avec un systeme d'oligonucleotides haute densite
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060166972A1 (en) * 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
WO2005097111A2 (fr) * 2004-03-26 2005-10-20 Merck & Co., Inc. Traitement des tremblements utilisant des agonistes inverses de l'histamine h3 ou des antagonistes de l'histamine h3
CA2721797C (fr) 2008-04-18 2018-02-27 Gary Zabow Microstructures magnetiques pour l'imagerie par resonance magnetique
JP6054303B2 (ja) 2010-12-30 2016-12-27 ファウンデーション メディシン インコーポレイテッドＦｏｕｎｄａｔｉｏｎ Ｍｅｄｉｃｉｎｅ， Ｉｎｃ． 腫瘍試料の多重遺伝子分析の最適化
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
US11281170B2 (en) 2015-12-29 2022-03-22 Jones And Malterer Technology Innovations Incorporated Multi-point synchronizable and scalable lighting control systems
AU2017246334C1 (en) 2016-04-04 2022-11-17 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using Trapidil
JP7730336B2 (ja) 2020-03-26 2025-08-27 シノピア バイオサイエンシーズ，インク． 同位体標識トラピジル誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117765A1 (en) * 2005-11-18 2007-05-24 Cornell Research Foundation Inc. Nicotinoyl riboside compositions and methods of use
US20090192111A1 (en) * 2007-12-01 2009-07-30 Asuragen, Inc. miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2017059113A1 (fr) * 2015-09-29 2017-04-06 Duke University Compositions et méthodes pour identifier et traiter des troubles associés à la dystonie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANTINI ET AL.: "L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice", J NEUROCHEM., vol. 108, no. 3, February 2009 (2009-02-01), pages 621 - 33, XP055483457 *

Also Published As

Publication number Publication date
JP7049683B2 (ja) 2022-04-07
US20230201205A1 (en) 2023-06-29
AU2017246334B2 (en) 2022-07-28
FI3442538T3 (fi) 2025-09-04
US20190328741A1 (en) 2019-10-31
US12268691B2 (en) 2025-04-08
AU2017246334A1 (en) 2018-11-15
EP3442538A4 (fr) 2019-11-20
AU2017246334C1 (en) 2022-11-17
CN116509869A (zh) 2023-08-01
EP3442538A2 (fr) 2019-02-20
US20180243307A1 (en) 2018-08-30
CA3054674A1 (fr) 2017-12-10
EP3442538B1 (fr) 2025-07-23
CN109310700A (zh) 2019-02-05
US11628170B2 (en) 2023-04-18
ES3039958T3 (en) 2025-10-27
JP2024095682A (ja) 2024-07-10
JP2019510826A (ja) 2019-04-18
WO2017176652A2 (fr) 2017-10-12
DK3442538T3 (da) 2025-09-01
US10350212B2 (en) 2019-07-16
JP2022088469A (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
WO2017176652A3 (fr) Traitement de syndrome extrapyramidal à l'aide de trapidil
WO2017191130A3 (fr) Inhibiteurs d'arginase et leurs applications thérapeutiques
MX2023002688A (es) Compuestos farmaceuticos de arilo, heteroarilo, y heterociclicos para el tratamiento de trastornos medicos.
WO2018067512A8 (fr) Composés spirocycliques
WO2016044556A3 (fr) Inhibiteurs d'arginine méthyltransférase et leurs utilisations
WO2016064082A3 (fr) Nouveau dérivé aminoalkyle benzothiazépine et son utilisation
WO2016149401A3 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
WO2017048702A8 (fr) Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
WO2017098328A3 (fr) Composés inhibiteurs thérapeutiques
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
WO2017218949A3 (fr) Macrocycles peptidomimétiques et leurs utilisations
WO2016089060A3 (fr) Dérivés hétérocycliques et leur utilisation
WO2016125192A3 (fr) Procédé de préparation de dolutégravir
EP3102036A4 (fr) Dérivé de carbonyle -naphto [2,3-b]furane 3-substitué dérivé ou sel pharmaceutiquement acceptable de celui-ci
MX2021007247A (es) Derivados de rapamicina.
HK1252614A1 (zh) 二环化合物
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
WO2016106284A3 (fr) Promédicaments de la créatine, compositions en contenant et leurs procédés d'utilisation
WO2015127284A3 (fr) Amides antimitotiques destinés au traitement du cancer et de troubles prolifératifs
EP3831365A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies atopiques
WO2018211324A8 (fr) Promédicaments pour traiter une maladie
WO2018211323A8 (fr) Composés hétérocycliques pour traiter une maladie
AU2020356348B2 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2019502544

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017779608

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017779608

Country of ref document: EP

Effective date: 20181105

ENP Entry into the national phase

Ref document number: 2017246334

Country of ref document: AU

Date of ref document: 20170403

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17779608

Country of ref document: EP

Kind code of ref document: A2

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17779608

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3054674

Country of ref document: CA

WWG Wipo information: grant in national office

Ref document number: 2017779608

Country of ref document: EP